UI Hospitals and Clinics

Clinical Trial Details

Short Title
Enzalutamide vs. enzalutamide, abiraterone and prednisone for metastatic prostate cancer
Official Title

Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer


Participants in this study have been diagnosed with progressive metastatic Castration Resistant Prostate Cancer (CRPC). The purpose of this study is to compare the overall survival of patients with progressive metastatic CRPC treated with either a) enzalutamide only or b) enzalutamide with abiraterone and prednisone. Approximately 60 participants will take part in this study at the University of Iowa.

Start Date
January 28, 2014
End Date
December 1, 2019
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Clarine Halvorsen, 319-356-3944

Hematology/ Oncology
201312774 ; cancer ; Phase three ; prostate ; Vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.